In the fiscal year 2023, the Global Parkinsons Disease Industryis poised to achieve an estimated worth of US$ 5.41 Billion, reflecting a notable increase from the US$ 4.82 Billion recorded in the fiscal year 2022. The projected growth trajectory for this decade, spanning from 2023 to 2033, anticipates a consistent annual growth rate of 12.2%, leading to a projected market value of US$ 17.12 Billion by the conclusion of 2033.
Parkinsons disease, a complex brain disorder characterized by the degeneration of nerve cells in a specific brain region, manifests in a myriad of ways, encompassing symptoms such as rigidity, emotional fluctuations, cognitive impairments, coordination and balance challenges, fluctuations in blood pressure, and cognitive functions. While Parkinsons disease remains incurable, it is crucial to recognize the availability of various treatment modalities, including surgical interventions, pharmaceutical therapies, and other advanced medical approaches.
Request a Sample Copy of the Report Now. https://www.futuremarketinsights.com/reports/sample/rep-gb-16241
When a patients medications are not functioning effectively, it can lead to an increase in Parkinsons disease (PD) symptoms including tremor and walking problems, which is known as an off episode. In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is used for Parkinsons disease. The medication offers patients with Parkinsons disease a brand-new non-dopaminergic once-daily oral treatment alternative. Such developments are expected to spur global growth in the Parkinsons disease market from 2023-2033.
Key Takeaways from the Market Study
The market is anticipated to expand as more drugs are approved for the treatment of Parkinsons disease and as there is a robust pipeline of novel medications being developed for the condition. comments a Future Market Insights analyst.
Discovering the assumptions behind the study. Ask an Analyst https://www.futuremarketinsights.com/ask-question/rep-gb-16241
Competitive Landscape
Some of the top players in the global Parkisons disease market are:
Some of the recent developments in this domain are:
Get Your Customized Impactful Report Now! https://www.futuremarketinsights.com/customization-available/rep-gb-16241
More Valuable Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Parkinsons disease Industry, presenting historical demand data (2018-2022) and forecast statistics from 2023 to 2033.
The study divulges essential insights on the market based on the Parkinsons disease industry by type (juvenile parkinson disease, young-onset parkinsons disease, idiopathic parkinson disease), by age (adult and pediatric), by diagnosis (CT Scan, MRI Scan, DaTSCAN-SPECT scan, PET Scan), by drug class (carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase b inhibitors, catechol o-methyltransferase inhibitors, anticholinergics, amantadine) and regions.
Key Segments Profiled in the Amyotrophic Lateral Sclerosis Industry Survey
Treatment:
Distribution Channel:
Region:
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware 19713, USA T: +1-845-579-5705 For Sales Enquiries:sales@futuremarketinsights.com Website:https://www.futuremarketinsights.com LinkedIn|Twitter|Blogs | YouTube
Read the original:
Global Parkinson's Disease Industry Set for US$17.12 Billion ... - PharmiWeb.com